AcuityBio Corp CEO Dr. John Schwartz tells Proactive Investors the biotech is developing an implant called ABC-103 that prevents post-surgical lung cancer occurrence.
Dr. Schwartz says ABC-103 is in the last stages of product development, and the company is pursuing Phase 1 clinical trials.
Original Article: AcuityBio developing 'breakthrough' implant treatment for lung cancer